Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
The treatment of metastatic renal-cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular endothelial growth factor (VEGF) inhibition can induce tumor shrinkage and increase progression-free survival and that immune checkpoint inhibitors can induce durable res...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2019-03, Vol.380 (12), p.1176-1178 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1178 |
|---|---|
| container_issue | 12 |
| container_start_page | 1176 |
| container_title | The New England journal of medicine |
| container_volume | 380 |
| creator | Escudier, Bernard |
| description | The treatment of metastatic renal-cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular endothelial growth factor (VEGF) inhibition can induce tumor shrinkage and increase progression-free survival and that immune checkpoint inhibitors can induce durable responses and increase overall survival among patients with this form of cancer. Guidelines for the treatment of metastatic renal-cell carcinoma have changed dramatically to recommend agents that target these two major pathways. In 2007, a trial showed that sunitinib, a tyrosine kinase inhibitor with potent VEGF inhibition, was superior to interferon alfa, and sunitinib became a new standard of . . . |
| doi_str_mv | 10.1056/NEJMe1900887 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2183641022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2183641022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-433308b6d2e5ae311d667554c530bd374ccd448e7a304dd0a48e9eed2226d3243</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgipvTm2cp6MGD1fxq0h6lbP5gmyDzXNLmDTuWdCbpYf-9kU0R8V3eO3z48vgidE7wLcGZuJuPn2dACozzXB6gIckYSznH4hANMaZ5ymXBBujE-xWOQ3hxjAYMS1lkVAzRvOxM3VoV2s4mi3dwarNNlE8mrfMhnbYWkoUDFQzYkLQ2mUFQPkTeJK9g1TotYb1OSuWa1nZGnaKjpVp7ONvvEXqbjBflYzp9eXgq76dpwwkPKWeM4bwWmkKmgBGihZBZxpuM4VozyZtGc56DVAxzrbGKdwGgKaVCM8rZCF3vcjeu--jBh8q0vomvKAtd7ytKciY4wZRGevmHrrrexdejooTlOcmkjOpmpxrXee9gWW1ca5TbVgRXXz1Xv3uO_GIf2tcG9A_-LjaCqx0wxlcWVub_nE_xOYDl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2213881577</pqid></control><display><type>article</type><title>Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Escudier, Bernard</creator><creatorcontrib>Escudier, Bernard</creatorcontrib><description>The treatment of metastatic renal-cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular endothelial growth factor (VEGF) inhibition can induce tumor shrinkage and increase progression-free survival and that immune checkpoint inhibitors can induce durable responses and increase overall survival among patients with this form of cancer. Guidelines for the treatment of metastatic renal-cell carcinoma have changed dramatically to recommend agents that target these two major pathways. In 2007, a trial showed that sunitinib, a tyrosine kinase inhibitor with potent VEGF inhibition, was superior to interferon alfa, and sunitinib became a new standard of . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe1900887</identifier><identifier>PMID: 30779526</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Inhibitor drugs ; Kidney cancer ; Kidney diseases ; Kinases ; Metastases ; Metastasis ; Protein-tyrosine kinase ; Renal cell carcinoma ; Targeted cancer therapy ; Vascular endothelial growth factor ; α-Interferon</subject><ispartof>The New England journal of medicine, 2019-03, Vol.380 (12), p.1176-1178</ispartof><rights>Copyright © 2019 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-433308b6d2e5ae311d667554c530bd374ccd448e7a304dd0a48e9eed2226d3243</citedby><cites>FETCH-LOGICAL-c414t-433308b6d2e5ae311d667554c530bd374ccd448e7a304dd0a48e9eed2226d3243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe1900887$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMe1900887$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30779526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Escudier, Bernard</creatorcontrib><title>Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The treatment of metastatic renal-cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular endothelial growth factor (VEGF) inhibition can induce tumor shrinkage and increase progression-free survival and that immune checkpoint inhibitors can induce durable responses and increase overall survival among patients with this form of cancer. Guidelines for the treatment of metastatic renal-cell carcinoma have changed dramatically to recommend agents that target these two major pathways. In 2007, a trial showed that sunitinib, a tyrosine kinase inhibitor with potent VEGF inhibition, was superior to interferon alfa, and sunitinib became a new standard of . . .</description><subject>Inhibitor drugs</subject><subject>Kidney cancer</subject><subject>Kidney diseases</subject><subject>Kinases</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Protein-tyrosine kinase</subject><subject>Renal cell carcinoma</subject><subject>Targeted cancer therapy</subject><subject>Vascular endothelial growth factor</subject><subject>α-Interferon</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0M9LwzAUB_AgipvTm2cp6MGD1fxq0h6lbP5gmyDzXNLmDTuWdCbpYf-9kU0R8V3eO3z48vgidE7wLcGZuJuPn2dACozzXB6gIckYSznH4hANMaZ5ymXBBujE-xWOQ3hxjAYMS1lkVAzRvOxM3VoV2s4mi3dwarNNlE8mrfMhnbYWkoUDFQzYkLQ2mUFQPkTeJK9g1TotYb1OSuWa1nZGnaKjpVp7ONvvEXqbjBflYzp9eXgq76dpwwkPKWeM4bwWmkKmgBGihZBZxpuM4VozyZtGc56DVAxzrbGKdwGgKaVCM8rZCF3vcjeu--jBh8q0vomvKAtd7ytKciY4wZRGevmHrrrexdejooTlOcmkjOpmpxrXee9gWW1ca5TbVgRXXz1Xv3uO_GIf2tcG9A_-LjaCqx0wxlcWVub_nE_xOYDl</recordid><startdate>20190321</startdate><enddate>20190321</enddate><creator>Escudier, Bernard</creator><general>Massachusetts Medical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20190321</creationdate><title>Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma</title><author>Escudier, Bernard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-433308b6d2e5ae311d667554c530bd374ccd448e7a304dd0a48e9eed2226d3243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Inhibitor drugs</topic><topic>Kidney cancer</topic><topic>Kidney diseases</topic><topic>Kinases</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Protein-tyrosine kinase</topic><topic>Renal cell carcinoma</topic><topic>Targeted cancer therapy</topic><topic>Vascular endothelial growth factor</topic><topic>α-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Escudier, Bernard</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Escudier, Bernard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2019-03-21</date><risdate>2019</risdate><volume>380</volume><issue>12</issue><spage>1176</spage><epage>1178</epage><pages>1176-1178</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>The treatment of metastatic renal-cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular endothelial growth factor (VEGF) inhibition can induce tumor shrinkage and increase progression-free survival and that immune checkpoint inhibitors can induce durable responses and increase overall survival among patients with this form of cancer. Guidelines for the treatment of metastatic renal-cell carcinoma have changed dramatically to recommend agents that target these two major pathways. In 2007, a trial showed that sunitinib, a tyrosine kinase inhibitor with potent VEGF inhibition, was superior to interferon alfa, and sunitinib became a new standard of . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>30779526</pmid><doi>10.1056/NEJMe1900887</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2019-03, Vol.380 (12), p.1176-1178 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2183641022 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Inhibitor drugs Kidney cancer Kidney diseases Kinases Metastases Metastasis Protein-tyrosine kinase Renal cell carcinoma Targeted cancer therapy Vascular endothelial growth factor α-Interferon |
| title | Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A00%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20Therapy%20as%20First-Line%20Treatment%20in%20Metastatic%20Renal-Cell%20Carcinoma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Escudier,%20Bernard&rft.date=2019-03-21&rft.volume=380&rft.issue=12&rft.spage=1176&rft.epage=1178&rft.pages=1176-1178&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe1900887&rft_dat=%3Cproquest_cross%3E2183641022%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2213881577&rft_id=info:pmid/30779526&rfr_iscdi=true |